Drug intelligence / Profile preview

psoralen + tazarotene

Development stage: Unknown
Modality: Small Molecules
Administration: Topical, Oral

Overview

A combination of psoralen and tazarotene. Tazarotene is a synthetic retinoid that works by slowing skin cell overgrowth and decreasing inflammation in conditions like psoriasis and acne. It undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. Psoralen is a photosensitizing agent typically used in combination with UVA light therapy (PUVA) for treating psoriasis. This specific combination is not documented as an approved single product in the search results.

Targets

RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)

Beyond the preview

Go deeper on psoralen + tazarotene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on psoralen + tazarotene.

Explore the full profile